Histomorphometry And Biomechanics Of Pharmaceutical Osteoporosis Bone Tissue Remodeling

Osteoporosis is a type of dysostosis disorder characterized by the damage caused to the microstructure of bone tissues, the continuous decreasing of bone matrixes and mineral bones proportionally, the shrinking of sclerotin, the decrease of the number of trabecular bones, and the increasing of bone fragility and the high risk of fracture. Among the above-mentioned characteristics of Osteoporosis, fracture was the most serious one; the most common fractures are vertebral compression fracture, Hip fracture, and barton fracture. The aim of pharmaceutical prevention and treatment of Osteoporosis is to maintain the bone mass and improve the bone quality, which could lead to the enhancement of the bone strength and the bone threshold. Postmenopausal Osteoporosis is one of the most common metabolic bone diseases for old and middle-aged women. With the increasing of people's average life expectancy, Osteoporosis has become a prominent issue for both public health and social life. Osteoporosis has become a worldwide disease which is greatly detrimental to the health of human beings, and has gained more and more attention from people all over the world.Purpose: After ovariectomy (OVX) operated on the rats and pharmaceutical intervention on the rats after OVX, the effects of the pharmaceutics on the prevention and treatment of Osteoporosis of were evaluated by means of the indexes of histomorphometry and bone biomechanics, and the pharmaceutical mechanism was discussed.Materials and Methods 24 female rats aged 9 months were randomly divided into 3 groups: sham-operation (SHAM-O) group, ovariectomy group (OVX) and OVX+ calcitonin group. The SHAM-O group were given the switch operation of intraperitoneal. The later two groups were ovariectomized bilaterally. The OVX+calcitonin group received miacalcicinjection 3IU/kg and osteoform 0.03g every day in consecutive 9 weeks after the operation. The other two groups were fed normally. After executed, kept back the humerus and the femur for making non-decalcified slice, then for making the analyse of bone tissue histomorphometry; kept back the rat's tibia for the compression experiment.The results based on histomorphometry indicated: The trabecular area, the trabecular thickness, and the trabecular number of the rats in the OVX group were significantly lower than those in the sham group (P<0.01); the trabecular separation of the rats in the OVX group was significantly higher than that in the sham group (P<0.01). The trabecular area, the trabecular thickness, and the trabecular number of the rats in the OVX+ calcitonin group were significantly higher than those in the OVX group (P<0.01); the trabecular separation of the rats in the OVX+ calcitonin group was significantly lower than that in the OVX group (P<0.01).. The trabecular area, the trabecular thickness, and the trabecular number of the rats in the OVX+ calcitonin group were significantly higher than those in the sham group(P<0.05); the trabecular separation of the rats in the OVX+ calcitonin group was significantly lower than that in the sham group(P<0.05). There is significant difference between the two groups (P<0.05 or P<0.01).The results based on biomechanics indicated: In the compression experiment of the rat's trabecular bone of tibia, the elastic module and the broken load of trabecular bones of rats in model groups were significantly lower than those in the sham group, and the same in calcitonin group were higher obviously than that in sham group and the model groups. But no significant change of biomechanics index of cortical bones was found.Conclusions: 1 .9-month-old female SD ovariectomized rats can make for the postmenopausal osteoporosis model successfully.2. OVX+ calcitonin could control the pathology of the high bone turnover rate of the ovariectomized rats effectively, prevent the further loss of the bone mass, and improve the biomechanics capability of os integumentale and cancellaced bone. Therefore OVX+ calcitonin could prevent and treat the postmenopausal osteoporosis to a certain extent.3.The pharmaceutical treatment could heighten general bone mineral density of model rats, improve trabecular structure, and increase trabecular area, trabecular plate thickness, trabecular number and trabecular nodes, and drop trabecular plate separation, and decrease free-ending trabecular, and shorten mineral aggradation and reduce star volume and space among trabeculars.